Antifungal Drug Susceptibility
Antifungal Drug Susceptibility - Related Videos
08:05
Candida albicans Biofilm Chip (CaBChip) for High-throughput Antifungal Drug Screening
0 Views •
Cited by 9 •
2012
We have developed a high-density microarray platform consisting of 3D nano-biofilms of C. albicans called CaBChip. The susceptibility profile of drugs tested on a CaBChip is comparable to the conventional 96-well plate model, suggesting that the fungal chip is ideally suited for true high-throughput screening of antifungal drugs.
07:19
A 96 Well Microtiter Plate-based Method for Monitoring Formation and Antifungal Susceptibility Testing of Candida albicans Biofilms
0 Views •
Cited by 105 •
2010
We describe a simple, rapid and robust method for the formation of Candida albicans biofilms using 96 well microtiter plates and its utility in antifungal susceptibility testing of cells within biofilms.
12:39
Antimicrobial Susceptibility Testing of Mycobacterium Tuberculosis Complex for First and Second Line Drugs by Broth Dilution in a Microtiter Plate Format
0 Views •
Cited by 29 •
2011
Antimicrobial susceptibility testing of Mycobacterium tuberculosis is challenging but critical for patient care. This microtiter plate format offers testing of 12 antimycobacterial drugs and provides minimum inhibitory concentration (MIC) values, which will aid in appropriate treatment.
10:00
Targeting Biofilm Associated Staphylococcus aureus Using Resazurin Based Drug-susceptibility Assay
0 Views •
Cited by 20 •
2016
Most bacterial infections produce a biofilm. By virtue of their environment, biofilm associated bacteria are often phenotypically drug resistant. Novel antibacterial molecules that kill bacteria in biofilms are thus a high priority. We establish an assay to quickly screen for antimicrobial compounds that are effective at eradicating biofilms.
03:48
An In Vitro Broth Microdilution Assay for the Screening of Antifungal Compounds
0 Views •
2025
This video demonstrates an in vitro assay to screen antifungal compounds using a broth microdilution assay. Test compounds are serially diluted in a microtiter plate and incubated with a fungal inoculum. Post-incubation, the plate is examined for wells without visible fungal growth to assess the antifungal potential of the test compounds and their minimum inhibitory concentration (MIC).
FAQs
The concentration series creates a graded exposure rather than a single yes-or-no drug test. Comparing fungal growth across those concentrations shows how the response changes as drug exposure increases, while the untreated control establishes the growth level expected without antifungal pressure. This relationship supports a consistent MIC determination.
An MIC condenses the concentration-response result into a value that can be compared among fungal isolates, compounds, or engineered formulations tested under the same standardized approach. Its usefulness depends on the growth comparison underlying it, because the value is tied to the observed inhibition relative to the untreated control.
Repeated susceptibility measurements can reveal changes in fungal response over time, making the assay useful for resistance surveillance. Rather than evaluating only whether a compound works once, surveillance uses susceptibility results to track emerging resistance and identify shifts that may affect drug selection. This makes the measurement relevant to treatment decisions and antifungal development.
In bioengineering, susceptibility results provide a biological performance readout for materials and delivery systems, not merely a chemical description of the antifungal compound. A formulation can therefore be screened by measuring its effect on fungal growth. This links engineered design choices with an observable outcome and helps prioritize candidates for further evaluation.
An assay begins by exposing a fungal isolate to a series of antifungal concentrations and includes an untreated control for comparison. Growth is then assessed across the exposure range, and the concentration associated with the defined inhibitory response is recorded as the MIC. This workflow converts growth observations into a standardized susceptibility result.
Core assay elements are the fungal isolate, the antifungal compound or engineered candidate, multiple drug concentrations, and an untreated comparison. In bioengineering studies, the candidate may be a newly engineered antifungal agent, a drug-delivery system, or a biomaterial. Linking these elements to growth measurement allows different designs to be evaluated through the same biological endpoint.
Researchers can apply these measurements when selecting among antifungal treatments, screening newly engineered agents, or monitoring resistance. The same general logic also supports testing bioengineered delivery systems and biomaterials, because their intended antifungal effect can be examined through fungal growth. Thus, susceptibility data connect therapeutic design with an experimentally measurable biological response.
Interpretation requires attention to what was tested: an isolate, a compound, or an engineered system. The MIC reports the concentration associated with inhibition under the assay conditions, while comparison with the untreated control confirms that the result reflects reduced fungal growth. This distinction helps relate material performance to antifungal activity without treating all candidates as equivalent.